Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Dermatology | Immunology | Family Medicine
Disease Category: Psoriatic Arthritis
Location: United States, MD

Clinical Trial Details

Overview

Research Study Summary

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis

Purpose

Do you have Psoriatic Arthritis? You may qualify to participate in a clinical research study.

Previously approved for the treatment of psoriasis, this agent is now being tested for BOTH biologic naïve as well as biologic exposed patients with psoriatic arthritis with active disease. This trial provides care for 108 weeks for biologic naïve patients and 60 weeks for patients with prior biologic exposure.

To Learn more
Phase

3

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Duration

108 Weeks

Facility Type

N/A

Contact

The Center for Rheumatology and Bone Research
2730 University Blvd West, Suite 306
Wheaton, MD 20902
Phone: 301 942-6610
Fax: 301 942-7833

View Map

Research Center Information: The Center for Rheumatology and Bone Research

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 170025

Date Last Changed: July 23, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.